NCT00452023 2024-12-11
Pegasys® in Patients With Myeloproliferative Diseases
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
5 trialsNCT01259856 2019-04-30
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Icahn School of Medicine at Mount Sinai
Phase 3 Completed
NCT02829775 2017-01-09
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Hoffmann-La Roche
Phase 2/3 Completed
NCT02736721 2016-09-20
Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)
Hoffmann-La Roche
Phase 3 Completed
NCT01392170 2015-05-04
Pegasys in Patients With Chronic Myeloid Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Terminated